Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Digoxin
Overview
What is Digoxin?
Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of The term “digitalis” is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence “glycosides”).
Digoxin is described chemically as (3β,5β,12β)-3-[(-2,6-dideoxy-β---hexopyranosyl-(1→4)--2,6-dideoxy-β---hexopyranosyl-(1→4)-2,6-dideoxy-β---hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide. lts molecular formula is CHO, its molecular weight is 780.95, and its structural formula is:
Digoxin exists as odorless white crystals that melt with decomposition above 230°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine.
Digoxin is supplied as 125 mcg (0.125 mg) or 250 mcg (0.25 mg) tablets for oral administration. Each tablet contains the labeled amount of digoxin USP and the following inactive ingredients:
125 mcg (0.125 mg):
250 mcg (0.25 mg):
What does Digoxin look like?
-120x150.jpg)
What are the available doses of Digoxin?
Sorry No records found.
What should I talk to my health care provider before I take Digoxin?
Sorry No records found
How should I use Digoxin?
Heart Failure:
General:
What interacts with Digoxin?
Sorry No Records found
What are the warnings of Digoxin?
Sorry No Records found
What are the precautions of Digoxin?
Sorry No Records found
What are the side effects of Digoxin?
In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when digoxin is used within the recommended dose range or therapeutic serum concentration range and when there is careful attention to concurrent medications and conditions.
Because some patients may be particularly susceptible to side effects with digoxin, the dosage of the drug should always be selected carefully and adjusted as the clinical condition of the patient warrants. In the past, when high doses of digoxin were used and little attention was paid to clinical status or concurrent medications, adverse reactions to digoxin were more frequent and severe. Cardiac adverse reactions accounted for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse reactions. However, available evidence suggests that the incidence and severity of digoxin toxicity has decreased substantially in recent years. In recent controlled clinical trials, in patients with predominantly mild to moderate heart failure, the incidence of adverse experiences was comparable in patients taking digoxin and in those taking placebo. In a large mortality trial, the incidence of hospitalization for suspected digoxin toxicity was 2% in patients taking digoxin compared to 0.9% in patients taking placebo. In this trial, the most common manifestations of digoxin toxicity included gastrointestinal and cardiac disturbances; CNS manifestations were less common.
Adults: Cardiac:
Gastrointestinal:
CNS:
Other:
Array
| Adverse Experience | Digoxin Patients | Placebo Patients |
| (n=123) | (n=125) | |
| Cardiac | ||
| Palpitation | 1 | 4 |
| Ventricular extrasystole | 1 | 1 |
| Tachycardia | 2 | 1 |
| Heart arrest | 1 | 1 |
| Gastrointestinal | ||
| Anorexia | 1 | 4 |
| Nausea | 4 | 2 |
| Vomiting | 2 | 1 |
| Diarrhea | 4 | 1 |
| Abdominal pain | 0 | 6 |
| CNS | ||
| Headache | 4 | 4 |
| Dizziness | 6 | 5 |
| Mental disturbances | 5 | 1 |
| Other | ||
| Rash | 2 | 1 |
| Death | 4 | 3 |
Infants and Children:
What should I look out for while using Digoxin?
Digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.
What might happen if I take too much Digoxin?
How should I store and handle Digoxin?
Store below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyStore below 30° C (86° F) [see USP].Dispense in a tight, light-resistant container as defined in USP/NF.BIBLIOGRAPHYAvailable on request.Manufactured by:Patheon Pharmaceuticals Inc.Cincinnati, OH 45215 USAFor: Corona, CA 92880This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central PharmacyDigoxin Tablets USP, 0.125 mg are yellow, round, scored on one side with imprint "W 40".Digoxin Tablets USP, 0.25 mg are white, round, scored on one side with imprint "WW 41".They are supplied by as follows:Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature] in a dry place.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lanoxicaps is a registered trademark of GlaxoSmithKline.Manufactured By: Eatontown, NJ 07724This Product was Repackaged By:State of Florida DOH Central Pharmacy
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Mechanism of Action:
Non-Clinical Toxicology
Digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.Due to the considerable variability of these interactions; the dosage of digoxin should be individualized when patients receive these medications concurrently. Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
Use in Patients with Impaired Renal Function:
In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when digoxin is used within the recommended dose range or therapeutic serum concentration range and when there is careful attention to concurrent medications and conditions.
Because some patients may be particularly susceptible to side effects with digoxin, the dosage of the drug should always be selected carefully and adjusted as the clinical condition of the patient warrants. In the past, when high doses of digoxin were used and little attention was paid to clinical status or concurrent medications, adverse reactions to digoxin were more frequent and severe. Cardiac adverse reactions accounted for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse reactions. However, available evidence suggests that the incidence and severity of digoxin toxicity has decreased substantially in recent years. In recent controlled clinical trials, in patients with predominantly mild to moderate heart failure, the incidence of adverse experiences was comparable in patients taking digoxin and in those taking placebo. In a large mortality trial, the incidence of hospitalization for suspected digoxin toxicity was 2% in patients taking digoxin compared to 0.9% in patients taking placebo. In this trial, the most common manifestations of digoxin toxicity included gastrointestinal and cardiac disturbances; CNS manifestations were less common.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).